Health economic modelling for the Med Tech companies
Early and comprehensive decision-analytic models to determine economic value proposition and inform healthcare decision-makers

This website uses cookies to ensure you get the best experience on our website. By carrying on browsing, you are giving your consent for us to set cookies.

Learn more
This sub-site ( is no longer updated. Please, proceed to our main web-site to learn about our services (
Health economics is an essential part of the value proposition for any medical technology. It demonstrates, whether technology is cost-saving or not. If it leads to higher cost, is it cost-effective for the healthcare system or not?

At the start of the life cycle for every technology, it is necessary to understand its economic value proposition, as it can drive the decision-making about its design or mode of use, necessary clinical studies and positioning towards the hospital and higher-level payers, and help to determine the appropriate pricing strategy.

Later on, health economic data become an important part of the reimbursement process. Health economic data (cost-effective and sometimes budget impact analysis) can be necessary for reimbursement processes in Belgium, England, France, Netherlands, Norway, and Switzerland. They are also important for negotiations with stakeholders in Germany and Italy.

There are a lot of challenges with the health economic evaluation of medical technologies: the complexity of costing of the index procedure, issues with the replacement of device, costing for capital equipment, incorporation of the data about the learning curve, and others. It requires a lot of expertise in the field of medical devices and IVD tests to take the right approach to health economic analysis.

MTRC is one the leading European consultancies in the field of market access for medical technologies and IVD tests. We can apply our knowledge of the health economic requirements of different stakeholders in Europe to the right design and methodology of the health economic analysis, help publish it or adapt it for use in reimbursement or health technology assessment applications.

How it works
During each stage of the project, we validate our approach and data selection with the client
Understanding the scope of work: the purpose (understand the value proposition, publication, use in reimbursement submissions), target audience, a country in scope, the perspective of the analysis (hospital vs health care system), type of analysis (cost-effectiveness vs cost vs budget impact)
Conceptualizing the model
Developing the conceptual overview of the model: type of the model (Markov model vs decision tree), health states and conditions, principles of progression of patient or disease
Data collection
Collection of the data to inform the model: clinical data (transition probabilities, effectiveness, safety), resource use and cost data, quality of life (utility) data
Development of the model
Building the model in MS Excel, quality checks and external validation to determine performance of the model
Writing the report
Development of the report or publication using ISPOR Good Practice Guidelines

Key benefits
Pan-European support
Analysis in 19 EU countries by the same vendor. Save money and time
Specialized Med Tech and IVD vendor
MTRC is one of the leading Med Tech consultancies in Europe
Knowledge of reimbursement and HTA requirements
MTRC has unique insights into requirements of key reimbursement and HTA stakeholders in majority of EU countries

Our services cover 19 European countries including Austria, Belgium, Czech Republic, Denmark, England, Finland, France, Germany, Hungary, Italy, the Netherlands, Norway, Poland, Romania, Russia, Spain, Sweden, Switzerland, and Turkey

Our publications
Our team has excellent track record with building and publishing health economic models
Veličković VM, Borisenko O, Svensson M, Spelman T, Siebert U. Congenital heart defect repair with ADAPT tissue engineered pericardium scaffold: An early-stage health economic model. PLoS One. 2018 Sep 27;13(9):e0204643.
O Borisenko, J Müller-Ehmsen, JA Lindenfeld, E Rafflenbeul, C Hamm. An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany. BMC Cardiovascular Disorders, 2018. 18:163.
Borisenko O, Lukyanov V, Ahmed A.R. Cost-utility analysis of bariatric surgery. Br J Surg. 2018 Apr 17. doi: 10.1002/bjs.10857.
Borisenko O, Lukyanov V, Debergh I, Dillemans B. Cost-effectiveness analysis of bariatric surgery for morbid obesity in Belgium. J Med Econ. 2018 Jan 10:1-9.
Sanchez-Santos R, Padin EM, Adam D, Borisenko O, Fernandez SE, Dacosta EC, Fernández SG, Vazquez JT, de Adana JCR, de la Cruz Vigo F. Bariatric surgery versus conservative management for morbidly obese patients in Spain: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res. 2017 Nov 30:1-10.
Bureau C, Adebayo D, Chalret de Rieu M, Elkrief L, Valla D, Peck-Radosavljevic M, McCune A, Vargas V, Simon-Talero M, Cordoba J, Angeli P, Rosi S, MacDonald S, Malago M, Stepanova M, Younossi ZM, Trepte C, Watson R, Borisenko O, Sun S, Inhaber N, Jalan R. Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenterrandomized controlled study. J Hepatol. 2017 Nov;67(5):940-949.
Borisenko O, Mann O, Duprée A. Cost-utility analysis of bariatric surgery compared with conventional medical management in Germany: a decision analytic modeling. BMC Surg. 2017 Aug 3;17(1):87.
O Borisenko, V Lukyanov, SP Johnsen, P Funch-Jensen. Cost analysis of bariatric surgery in Denmark made with a decision-analytic model. Dan Med J 2017;64(8):A5401
Lucchese M, Borisenko O, Mantovani LG, Cortesi PA, Cesana G, Adam D, Burdukova E, Lukyanov V, Di Lorenzo N. Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling. Obes Facts. 2017 Jun 10;10(3):261-272.
Borisenko O, Haude M, Hoppe UC, Siminiak T, Lipiecki J, Goldberg SL, Mehta N, Bouknight OV, Bjessmo S, Reuter DG. Cost-utility analysis of percutaneous mitral valve repair in inoperable patients with functional mitral regurgitation in German settings. BMC Cardiovasc Disord. 2015 May. 14;15(1):43.
Borisenko O, Adam D, Funch-Jensen P, Ahmed R Ahmed, Zhang R, Colpan Z, Hedenbro J. Bariatric surgery can lead to net cost savings to health care systems: results from a comprehensive European decision analytic model. Obes Surg. 2015 Sep;25(9):1559-68.
Borisenko O, Wylie G, Payne J, Bjessmo S, Smith J, Firmin R, Yonan N. The cost impact of short-term ventricular assist devices and extracorporeal life support systems therapies on the National Health Service in the UK. Interact Cardiovasc Thorac Surg. 2014 Jul;19(1):41-8.
Borisenko O, Beige J, Lovett EG, Hoppe UC, Bjessmo S. Cost-Effectiveness of Barostim Therapy for the Treatment of Resistant Hypertension in European Settings. J Hypertens. 2014 Mar;32(3):681-92.
Roos JB, Doshi SN, Konorza T, Palacios I, Schreiber T, Borisenko OV, Henriques JP. The cost-effectiveness of a new percutaneous ventricular assist device for high-risk PCI patients: mid-stage evaluation from the European perspective. J Med Econ. 2013;16(3):381-90.

About MTRC
A specialized Med Tech reimbursement consultancy
17 out of top 30 global Med Tech companies routinely use reimbursement services of MTRC

Coverage of 19 European markets with consulting services

>130 reimbursement projects per year

15 full-time employees, located in six European countries. In-house coverage of key languages (French, German, Italian, Spanish, Polish, Russian, Turkish)

ISO 9001:2015 certified with the United Kingdom Accreditation Service, UKAS

Main websites: Med Tech, Online school in market access
Contact us
Contact us to learn more about our capabilities to address your needs